Nestle’s health science division has acquired US-based Pamlab as part of the company’s startegy to expand its presence in medical nutrition.
Nestle said yesterday (26 February) that it has bought Pamlab for an undisclosed fee.
Go deeper with GlobalData
The Swiss food giant runs its health science division as a fully owned subsidiary and has spent the past year building its presence in the area of medical nutrition.
Pamlab produces a range of “medical food products for use under medical supervision in the nutritional management of patients with mild cognitive impairment, depression and diabetic peripheral neuropathy”, Nestle said.
One of its products, Metanx, helps to regulate metabolic processes associated with brain health in diabetes patients. It also makes Deplin, which is used to provide nutritional support for those taking antidepressants.
In 2012, Nestlé Health Science agreed to form a 50/50 joint venture named Nutrition Science Partners Ltd, to develop nutritional and medicinal products derived from plants to address gastrointestinal disorders. The transaction is still subject to regulatory approval.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
